Arfolitixorin - en läkemedelskandidat
för behandling av kolorektal cancer

Fler än 370 000 CRC patienter
skulle i framtiden kunna
behandlas med arfolitixorin

Fas III registreringsstudien - AGENT

AGENT-studien med arfolitixorin

pågår vid mer än 70 sjukhus

i USA, Kanada och Europa

Se hur arfolitixorin
fungerar i cancerceller

Previous

Next

Startsidan 2

Pressreleaser & Senaste nyheter

Patent godkänt i Japan för Isofols läkemedelskandidat arfolitixorin

Patent godkänt i Japan för Isofols läkemedelskandidat arfolitixorin

december 20, 2019 by

GÖTEBORG, Sverige, 20 december, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL). Ett patent för den aktiva…

Patentgodkännande i USA för att identifiera hur patienter svarar på folatbaserad cancerbehandling

Patentgodkännande i USA för att identifiera hur patienter svarar på folatbaserad cancerbehandling

december 13, 2019 by

GÖTEBORG, Sverige, 13 december, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), tillkännager idag ett godkännande från…

Isofol meddelar att Lars Lind, Malin Björkmo, Bo Lundgren och Mats-Ola Palm utsetts som ledamöter i bolagets valberedning

Isofol meddelar att Lars Lind, Malin Björkmo, Bo Lundgren och Mats-Ola Palm utsetts som ledamöter i bolagets valberedning

december 3, 2019 by

GÖTEBORG, Sverige, 3 december 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), tillkännagav idag att enligt de…

Kommande Event

januari 23, 2020 - januari 25, 2020
ASCO Gastrointestinal Cancers Symposium, San Francisco, USA >>
mars 03, 2020 - mars 04, 2020
Carnegie Nordic Healthcare Seminar
Isofol presenterar vid Carnegie Nordic Healthcare Seminar i Stockholm.

©2018 Isofol Medical AB, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden. Isofol Medical AB has the exclusive right to develop Modufolin® and has the exclusive license to the Modufolin® trademark

Isofol´s Glossary

Isofols webbplats använder cookies för att förbättra och anpassa ditt besök. Genom att fortsätta accepterar du detta.
Acceptera Läs mer
Integritets & cookie Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Nödvändigt Alltid aktiverad

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.